Palatin Technologies, Inc.

Clinical trials sponsored by Palatin Technologies, Inc., explained in plain language.

Palatin Technologies, Inc. PTN NYSE AMERICAN

Develops peptide-based therapies for inflammatory and sexual disorders.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Terminated 1

Heart failure drug trial halted early – what went wrong?

Disease control Stopped early

This small study tested a drug called PL-3994 in 15 people with a type of heart failure where the heart pumps normally but doesn't relax properly. The goal was to see if the drug improved heart function and if effects differed between men and women. The trial was terminated early…

Phase 2 • Sponsor: Palatin Technologies, Inc • Aim: Disease control

Last updated Jun 27, 2026 08:04 UTC

Palatin Technologies, Inc.

Heart failure drug trial halted early – what went wrong?